These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10584686)

  • 1. Nabilone increases choreatic movements in Huntington's disease.
    Müller-Vahl KR; Schneider U; Emrich HM
    Mov Disord; 1999 Nov; 14(6):1038-40. PubMed ID: 10584686
    [No Abstract]   [Full Text] [Related]  

  • 2. Nabilone could treat chorea and irritability in Huntington's disease.
    Curtis A; Rickards H
    J Neuropsychiatry Clin Neurosci; 2006; 18(4):553-4. PubMed ID: 17135385
    [No Abstract]   [Full Text] [Related]  

  • 3. [Patients at the memory clinic with choreatic movements].
    Klompe LA; Eerenberg JG; Verschoor CJ
    Tijdschr Gerontol Geriatr; 2011 Feb; 42(1):29-33. PubMed ID: 21400960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Choreatic syndrome at 79 years old: late manifestation of Huntington's chorea].
    Vachalova I; Golden V; Großkopf J; Heckmann JG
    Nervenarzt; 2013 Dec; 84(12):1502-3. PubMed ID: 24264646
    [No Abstract]   [Full Text] [Related]  

  • 5. Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report.
    Chari S; Quraishi SH; Jainer AK
    Pharmacopsychiatry; 2003 Jan; 36(1):41-3. PubMed ID: 12649776
    [No Abstract]   [Full Text] [Related]  

  • 6. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cerebrospinal fluid metabolism of biogenic amines in Huntington chorea].
    Loeb C; Roccatagliata G; Albano C; Lamedica G; Abbruzzese G; Canini S
    Schweiz Arch Neurol Neurochir Psychiatr; 1976; 119(2):333-42. PubMed ID: 137520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of coenzyme Q10 tolerability in Huntington's disease.
    Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I
    Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Tribl GG; Költringer P
    Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
    Walters AS; McHale D; Sage JI; Hening WA; Bergen M
    Clin Neuropharmacol; 1990 Jun; 13(3):236-40. PubMed ID: 2141544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of remacemide hydrochloride in Huntington's disease.
    Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I
    Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.
    Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW
    Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Amisulpride in Huntington's disease].
    Saft C; Andrich J; Kraus PH; Przuntek H
    Psychiatr Prax; 2005 Oct; 32(7):363-6. PubMed ID: 16220421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.
    Jacobs M; Hart EP; van Zwet EW; Bentivoglio AR; Burgunder JM; Craufurd D; Reilmann R; Saft C; Roos RA;
    J Neurol; 2016 Oct; 263(10):2080-5. PubMed ID: 27435968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease.
    Hart EP; Marinus J; Burgunder JM; Bentivoglio AR; Craufurd D; Reilmann R; Saft C; Roos RA;
    Mov Disord; 2013 Jul; 28(8):1142-5. PubMed ID: 23495076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids for Treatment of Dystonia in Huntington's Disease.
    Saft C; von Hein SM; Lücke T; Thiels C; Peball M; Djamshidian A; Heim B; Seppi K
    J Huntingtons Dis; 2018; 7(2):167-173. PubMed ID: 29562549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntington's chorea. A random process.
    Tan BK; Mastebroek HA; Zaagman WH
    Clin Neurol Neurosurg; 1976; 79(3):215-21. PubMed ID: 141992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homovanilic acid in Huntington's disease and Sydenham's chorea.
    Cunha L; Oliveira CR; Diniz M; Amaral R; Conçalves AF; Pio-Abreu J
    J Neurol Neurosurg Psychiatry; 1981 Mar; 44(3):258-61. PubMed ID: 6453208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome.
    Reuter I; Hu MT; Andrews TC; Brooks DJ; Clough C; Chaudhuri KR
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):238-41. PubMed ID: 10644798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dexamethasone therapy in Huntington chorea: preliminary results].
    Nuti A; Maremmani C; Ceravolo R; Pavese N; Bonuccelli U; Muratorio A
    Riv Neurol; 1991; 61(6):225-7. PubMed ID: 1839936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.